Head and Neck cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight, "Head and Neck cancer Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the Head and Neck cancer pipeline landscape. It covers the Head and Neck cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Head and Neck cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key highlights from the Head and Neck Cancer Pipeline Report

*
DelveInsight's Head and Neck Cancer pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Head and Neck Cancer treatment.

*
The leading Head and Neck Cancer Companies working in the market includes Debiopharm/Merck, AstraZeneca/MedImmune, Eisai Co Ltd/Merck & Co, Kura Oncology, Cellectar Biosciences, Galera Therapeutics, Inc., BioMimetix JV, LLC, Bristol-Myers Squibb, QBiotics Group Limited, Alentis Therapeutics AG, Coordination Pharmaceuticals, Inc., Genmab, Merck Sharp & Dohme LLC, Immunovative Therapies, Ltd., TyrNovo Ltd, BioNTech SE, Aveta Biomics, Inc., Pfizer, and Cue Biopharma are prominent players within the pharmaceutical and biotech industries.

*
Promising Head and Neck Cancer Therapies in the various stages of development include Gefitinib, Cisplatin, Fluorouracil, RiMO-301, Pembrolizumab, Erlotinib, and others.

*
May 2024:- Ascendis Pharma Oncology - BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 /, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 /, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage III/IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC).

*
April 2024:- M.D. Anderson Cancer Center - Randomized, Placebo-Controlled, Phase 2 Study Of Induction Chemotherapy With Cisplatin/Carboplatin, And Docetaxel With Or Without Erlotinib In Patients With Head And Neck Squamous Cell Carcinomas Amenable For Surgical Resection. The goal of this clinical research study is to learn if adding erlotinib to a standard chemotherapy combination (docetaxel and either cisplatin or carboplatin) can help to control SCCHN. The safety of this drug combination will also be studied.

Request a sample and discover the recent advances in Head and Neck Cancer @ Head and Neck Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Head and Neck Cancer Overview

Head and neck cancer is a collective term that includes several different types of cancers. Cancers of the head and neck are categorized by the area in which they begin. This includes the mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands. The most common type of head and neck cancer is squamous cell carcinoma of the head and neck (HNSCCA). Most HNSCCA begins in the layer of flat cells (the epithelium) which line the structures of the upper aero digestive tract, including the mouth, throat, and voice box.

Head and Neck Cancer Emerging Drugs Profile

*
Xevinapant : Merck

Xevinapant is a potent, orally available, inhibitor of IAPs (Inhibitor of Apoptosis Proteins). IAP inhibitors restore sensitivity to apoptosis in cancer cells and thereby deprive them of one of their major resistance mechanisms. The drug is under an exclusive license agreement with Merck. Xevinapant received FDA granted Breakthrough Therapy Designation. Currently it is in Phase III stage of clinical trial evaluation to treat Head and Neck Cancer.

*
Durvalumab : AstraZeneca

Durvalumab (MEDI4736) is an investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. The drug blocks these signals, countering the tumor's immune-evading tactics. MEDI4736 is being developed, alongside other immunotherapies, to empower the patient's immune system and attack the cancer. Currently being evaluated in the Phase III studies for the treatment of head and neck cancer.

*
Tipifarnib : Kura Oncology

Tipifarnib is an oral, small molecule drug candidate and highly selective inhibitor of farnesyltransferase. The drug is in the Phase II stage of clinical trials for the treatment of head and neck cancer.

*
Iopofosine: Cellectar Biosciences

Lopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The drug is being developed in collaboration with University of Wisconsin-Madison. The drug is in Phase I stage of clinical trials for the treatment of head and neck cancer.

Learn more about Head and Neck Cancer in clinical trials @ Head and Neck Cancer Drugs [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Head and Neck Cancer Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Head and Neck cancer. The companies which have their Head and Neck cancer drug candidates in the most advanced stage, i.e. phase III include, Merck.

DelveInsight's Head and Neck Cancer Pipeline Report covers around 120+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Discover more about Head and Neck Cancer in development @ Head and Neck Cancer Clinical Trials [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Head and Neck Cancer Companies

Debiopharm/Merck, AstraZeneca/MedImmune, Eisai Co Ltd/Merck & Co, Kura Oncology, Cellectar Biosciences, Galera Therapeutics, Inc., BioMimetix JV, LLC, Bristol-Myers Squibb, QBiotics Group Limited, Alentis Therapeutics AG, Coordination Pharmaceuticals, Inc., Genmab, Merck Sharp & Dohme LLC, Immunovative Therapies, Ltd., TyrNovo Ltd, BioNTech SE, Aveta Biomics, Inc., Pfizer, and Cue Biopharma and others.

Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Head and Neck Cancer Products have been categorized under various Molecule types such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

To know more about Head and Neck Cancer , visit @ Head and Neck Cancer Segmentation [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Head and Neck Cancer Pipeline Report

*
Coverage- Global

*
Head and Neck Cancer Companies- Debiopharm/Merck, AstraZeneca/MedImmune, Eisai Co Ltd/Merck & Co, Kura Oncology, Cellectar Biosciences, Galera Therapeutics, Inc., BioMimetix JV, LLC, Bristol-Myers Squibb, QBiotics Group Limited, Alentis Therapeutics AG, Coordination Pharmaceuticals, Inc., Genmab, Merck Sharp & Dohme LLC, Immunovative Therapies, Ltd., TyrNovo Ltd, BioNTech SE, Aveta Biomics, Inc., Pfizer, and Cue Biopharma and others.

*
Head and Neck Cancer Therapies- Gefitinib, Cisplatin, Fluorouracil, RiMO-301, Pembrolizumab, Erlotinib, and others.

*
Head and Neck Cancer Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For further information on the Head and Neck Cancer Pipeline Therapeutics, reach out @ Head and Neck Cancer Products Development [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

*
Introduction

*
Executive Summary

*
Head and Neck Cancer : Overview

*
Pipeline Therapeutics

*
Therapeutic Assessment

*
Late Stage Products (Phase III)

*
Xevinapant : Merck

*
Drug profiles in the detailed report.....

*
Mid Stage Products (Phase II)

*
Tipifarnib : Kura Oncology

*
Early Stage Products (Phase I)

*
Iopofosine : Cellectar Biosciences

*
Inactive Products

*
Head and Neck Cancer Key Companies

*
Head and Neck Cancer Key Products

*
Head and Neck Cancer - Unmet Needs

*
Head and Neck Cancer - Market Drivers and Barriers

*
Head and Neck Cancer - Future Perspectives and Conclusion

*
Head and Neck Cancer Analyst Views

*
Head and Neck Cancer Key Companies

*
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=head-and-neck-cancer-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.